

LETTER

Open Access



Update to “guidelines on COVID-19 vaccination in patients with immune-mediated rheumatic diseases: a Brazilian Society of Rheumatology task force”

Anna Carolina Faria Moreira Gomes Tavares¹, Ana Karla Guedes de Melo^{2*} , Vítor Alves Cruz³, Lilian David de Azevedo Valadares⁴, Ricardo Machado Xavier⁵, Viviane Angelina de Souza⁶ and Gecilmara Cristina Salviato Pileggi⁷

The Committee of Endemic and Infectious Diseases and the Executive Board of the Brazilian Society of Rheumatology (SBR) proposed an update to the “Guidelines on COVID-19 vaccination in patients with immune-mediated rheumatic diseases: a Brazilian Society of Rheumatology task force” [1] based on recently published scientific evidence [2] and on the new recommendations of the Brazilian National Immunization Program (NIP) for vaccination of immunocompromised persons [3, 4]. According to the NIP documents [3, 4], the primary vaccination series is composed of three doses of Coronavac or ChAdOx-1 (AstraZeneca) or mRNA BNT162b2 (Pfizer), or two doses of Ad26.COV2.S (Janssen). A booster is recommended four months after the primary vaccination schedule, preferably with an mRNA vaccine or a non-replicating viral vector. The NIP recommendations for immunocompromised patients, endorsed by the SBR, are summarized below:

1. An 8-week interval between the second and third doses was chosen over a shorter interval of 3 weeks

to potentiate vaccine responses and minimize possible adverse events [3];

2. Persons 18 years and older who received the three-dose primary vaccination series should receive a fourth booster dose four months after the third, preferably with AstraZeneca, Janssen or Pfizer [3];
3. Persons 18 years and older who received one dose Janssen vaccine should complete the primary vaccination series with a second dose of the Janssen vaccine eight weeks after the first dose and receive a third booster dose four months after the second dose, preferably AstraZeneca, Janssen, or Pfizer [3];
4. Pregnant and postpartum women (up to 45 days following end of pregnancy) should receive a booster dose four months after the primary vaccination series of Pfizer vaccine and, if not available, Coronavac vaccine [3];
5. Adolescents from 12 to 17 years old should receive three doses in the primary vaccination series and a fourth booster dose Pfizer four months after the third one [3];
6. Children from 5 to 11 years old should receive the Pfizer two-dose primary vaccination series with an 8-week interval between the first and second doses [4].

*Correspondence: anakarlagmelo@gmail.com

² Lauro Wanderley University Hospital, Federal University of Paraíba, R. Tab. Stanislaui Eloy, 585 - Castelo Branco, João Pessoa, Paraíba 58050-585, Brazil
Full list of author information is available at the end of the article



Abbreviations

SBR: Brazilian Society of Rheumatology; NIP: National Immunization Program.

Acknowledgements

Not applicable

Author contributions

All authors read and approved the final manuscript.

Funding

Not applicable.

Availability of data and materials

Not applicable.

Declarations**Ethics approval and consent to participate**

Not applicable.

Consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

Author details

¹Clinical Hospital, Federal University of Minas Gerais, Belo Horizonte, Brazil. ²Lauro Wanderley University Hospital, Federal University of Paraíba, R. Tab. Stanislau Eloy, 585 - Castelo Branco, João Pessoa, Paraíba 58050-585, Brazil. ³Clinical Hospital, Federal University of Goiás, Goiânia, Brazil. ⁴Getúlio Vargas Hospital, Recife, Brazil. ⁵Clinical Hospital, Federal University of Rio Grande Do Sul, Porto Alegre, Brazil. ⁶Federal University, Juiz de Fora, Brazil. ⁷Federal University of São Paulo, São Paulo, Brazil.

Received: 12 April 2022 Accepted: 26 June 2022

Published online: 28 July 2022

References

1. Tavares ACFMG, Melo AKG, Cruz VA, Souza VA, Carvalho JS, Machado KLLL, et al. Guidelines on COVID-19 vaccination in patients with immune-mediated rheumatic diseases: a Brazilian Society of Rheumatology task force. *Adv Rheumatol.* 2022;62:3. <https://doi.org/10.1186/s42358-022-00234-7>.
2. Bar-On YM, Goldberg Y, Mande M, Bodenheimer O, Freedman L, Kalkstein N, et al. Protection of BNT162b2 vaccine booster against COVID-19 in Israel. *N Engl J Med.* 2021;385:1393–400. <https://doi.org/10.1056/NEJMoA2114255>.
3. MINISTÉRIO DA SAÚDE. Nota Técnica nº 8/2022- SECOVID/GAB/SECOVID/MS: Recomendação para administração do esquema primário e dose de reforço de vacinas contra a COVID-19 em pessoas imunocomprometidas a partir de 12 anos de idade. Brasília, 2022.
4. MINISTÉRIO DA SAÚDE. Nota Técnica nº 2/2022- SECOVID/GAB/SECOVID/MS: Vacinação não obrigatória de crianças de 05 a 11 anos contra Covid-19 durante a pandemia da Covid-19. Brasília, 2022.

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Ready to submit your research? Choose BMC and benefit from:

- fast, convenient online submission
- thorough peer review by experienced researchers in your field
- rapid publication on acceptance
- support for research data, including large and complex data types
- gold Open Access which fosters wider collaboration and increased citations
- maximum visibility for your research: over 100M website views per year

At BMC, research is always in progress.

Learn more biomedcentral.com/submissions

